CorMedix COO uses 8,076 shares for option costs

Rhea-AI Filing Summary

CorMedix Inc. (CRMD) reported that officer Elizabeth Hurlburt, Chief Operating Officer, had 8,076 shares of common stock disposed of on 2026-08-29 in a transaction coded F, described as a payment of exercise price or tax liability by delivering or withholding securities. Following this withholding transaction, she directly holds 270,463 shares of CorMedix common stock.

Insider Trade Summary

Net Seller: 8,076 shares

Net Sell 1 txn

Insider Hurlburt Elizabeth

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	8,076	$8.30	$67K

Holdings After Transaction: Common Stock — 270,463 shares (Direct)

Key Figures

Shares disposed for exercise price or tax liability: 8,076 shares Transaction price per share: $8.30 per share Shares held after transaction: 270,463 shares

3 metrics

Shares disposed for exercise price or tax liability 8,076 shares Code F transaction on 2026-08-29

Transaction price per share $8.30 per share Price reported for the 8,076-share code F transaction

Shares held after transaction 270,463 shares Direct ownership following the 2026-08-29 transaction

Key Terms

Common Stock, Payment of exercise price or tax liability by delivering or withholding securities, direct or indirect

3 terms

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Payment of exercise price or tax liability by delivering or withholding securities financial

"transaction_code_description: "Payment of exercise price or tax liability by...""

direct or indirect financial

"direct_or_indirect: "D" indicating direct ownership type"

FAQ

What insider transaction did CorMedix Inc. (CRMD) report for Elizabeth Hurlburt?

CorMedix reported that Elizabeth Hurlburt had 8,076 shares of common stock disposed of on 2026-08-29 in a code F transaction used for payment of exercise price or tax liability by delivering or withholding shares.

How many CorMedix (CRMD) shares does Elizabeth Hurlburt hold after the reported transaction?

After the transaction, Elizabeth Hurlburt directly holds 270,463 shares of CorMedix common stock, as reported in the Form 4 filing.

What does the code F transaction mean in the CorMedix (CRMD) Form 4 for Elizabeth Hurlburt?

The filing states that code F represents “Payment of exercise price or tax liability by delivering or withholding securities”, indicating shares were withheld or delivered rather than sold in an open-market trade.

Was the CorMedix (CRMD) Form 4 transaction by Elizabeth Hurlburt part of a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not checked (aff_10b5_one is false), so the transaction is not affirmatively reported as occurring under a Rule 10b5-1 trading plan.

What price per share is reported for Elizabeth Hurlburt’s CorMedix (CRMD) transaction?

The Form 4 reports a transaction price of $8.30 per share for the 8,076 shares used in the payment of exercise price or tax liability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 08:18 PM Accepted by SEC EDGAR 09/01/2026 - 08:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hurlburt Elizabeth

(Last) (First) (Middle)

C/O CORMEDIX INC.

389 INTERPACE PKWY, SUITE 450

(Street)

PARSIPPANY NEW JERSEY 07054

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/29/2026		F		8,076	D	$8.3	270,463	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Chief Operating & Commercial Officer

	/s/ Beth Zelnick Kaufman, attorney-in-fact	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)